Treatment-resistant depression
Structured. Supervised. Clinically intentional.
When depression hasn’t responded to standard treatment, more of the same is rarely the answer. Spravato® offers a clinically different option, delivered with medical oversight and clear goals.
At Mercurius, Spravato® isn’t treated as a last resort. It is a focused, evidence-based pathway for patients who need a different mechanism of care.
What is Spravato®?
Spravato® (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression and for certain adults with major depressive disorder.
Traditional antidepressants work gradually through serotonin pathways. Spravato® instead acts on NMDA receptors, influencing glutamate — a system closely tied to mood regulation, neuroplasticity and emotional processing. That difference matters when other treatments haven’t worked.
Certified provider
Certified Spravato® provider
Spravato® is never prescribed casually. As a certified provider, we deliver it with intention, structure and accountability:
- Treatment takes place on-site, in our office
- Dosing follows strict clinical protocols
- Every session is medically supervised
- Ongoing psychiatric follow-up is built in
Is it right for you?
Who Spravato® may help
Spravato® may be appropriate if you:
- Have tried several antidepressants without adequate relief
- Continue to experience depression despite consistent treatment
- Need an option beyond medication adjustments alone
- Would benefit from a more biologically targeted approach
Eligibility is determined through clinical screening.
The process
How treatment works
Details matter, and structure protects outcomes. Spravato® treatment at Mercurius includes:
- Comprehensive evaluationA full psychiatric assessment confirms whether Spravato® is clinically appropriate.
- On-site administrationYou self-administer the nasal spray under medical supervision in a controlled setting.
- Monitoring periodYou are observed after each session to ensure safety and stability before you leave.
- Ongoing oversightProgress is monitored, reviewed and adjusted — never left on autopilot.
Planning for treatment days
Spravato® requires a monitoring period of at least two hours after each dose, so plan for a longer visit. You should not drive or operate machinery until the next day after a restful sleep — please arrange a ride home before each appointment.
Education is part of care
You deserve to understand what Spravato® does, why it works differently, and what realistic outcomes look like. Informed patients make stronger, more sustainable progress.
Don’t wait years to explore it
Many people discover Spravato® only after years of trial and error. If standard treatments haven’t brought relief, exploring a different clinical pathway sooner can change the trajectory.
Ask whether Spravato® is right for you
If you’re looking for structured, supervised care for treatment-resistant depression, we invite you to learn more.